Group 1 - Dow futures rose by 0.09%, S&P 500 futures increased by 0.10%, and Nasdaq futures gained 0.07% [1] - Philips reported Q4 2025 earnings with a 1% year-over-year sales increase to €5.1 billion and an adjusted EBITA of €770 million, exceeding market expectations, leading to a 6.89% stock increase [2] - Cisco launched a new AI network chip, "Silicon One G300," expected to enhance AI computing task speeds by 28%, utilizing TSMC's 3nm process technology [2] Group 2 - Alphabet, Google's parent company, initiated its first issuance of Swiss franc bonds and British pound bonds, with maturities ranging from 3 to 100 years [2] - TSMC reported January sales of NT$401.26 billion, a 36.8% year-over-year increase and a 19.8% month-over-month rise, leading to a 3.09% stock increase [2] - BP's Q4 earnings showed a benchmark replacement cost profit of $1.54 billion, aligning with analyst expectations, but the full-year net profit of $7.49 billion fell short of the $7.58 billion forecast, resulting in a 4.9% stock decline [2] Group 3 - AstraZeneca's 2025 total revenue reached $58.739 billion, an 8% year-over-year increase, with growth in biopharmaceuticals, oncology, and rare diseases, and plans for significant investment in China [3] - AppLovin's stock rose by 3.5% after a short-seller retracted allegations against a major shareholder, ensuring the protection of legal rights [3] Group 4 - Eli Lilly announced a $2.4 billion acquisition of Orna Therapeutics to gain CAR-T therapy technology, aiming to produce cells in vivo rather than in the lab [4] Group 5 - Optical communication stocks saw a pre-market surge, with Redo Technology up over 17%, Astera Labs rising over 5%, and Corning increasing by over 1% [5]

2月7日，强生卌述无银公益之旅——2026年"此地无银"公益项目启动会在强生创新制药西安工厂举行。 来自全国各地的近百位皮肤科专家及患者组织代表齐聚古城，携手共绘"中国皮科无银生态蓝图"，并用 两张"处方"为中国700 万银屑病患者学业、职业公平发展注入专业力量与人文温度，推动中国银屑病领 域公益实践迈上多元新高度。 "无银"诊疗处方点亮治愈希望，公益行动回应未尽之需 超过60%的银屑病患者认为反复发作的皮损给其工作、学习带来困扰，37%的患者因患银屑病失业，中 重度患者失业率更是高达48%，逾半数患者因心理压力减少社会接触 ……在活动现场的"无银之路"公益 展区，一系列数据不仅立体呈现出银屑病患者的学业、职业发展困境，也揭示了由此造成的沉重社会负 担。这些数字背后鲜活的故事更让在场嘉宾直观感受到，银屑病患者在疾病治疗之外的未尽之需，亟待 社会各界的关注与支持。正如银屑病病友互助网创始人史星翔所言："100%的银屑病患者，都应该享有 公平的发展机会。" 旨在支持银屑病患者的治疗与发展需求，强生创新制药自2024年启动了"此地无银"公益项目，通过创新 公益形式，逐步构建银屑病患者公平发展支持体系。2026年，项 ...

A live audio webcast of the presentation will be accessible through Johnson & Johnson's Investor Relations website at www.investor.jnj.com. An archived edition of the session will be available later that day. The audio webcast replay will be available approximately 48 hours after the webcast. thth NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Johnson & Johnson (NYSE: JNJ) will present at the Barclays 28 Annual Global Healthcare Conference on Tuesday, March 10, 2026. Management will participate in a Fireside Chat at ...

Core Insights - Johnson & Johnson (JNJ) has a diverse revenue stream in its Innovative Medicine division, with sales reaching $60.4 billion in 2025, reflecting a 5.3% operational growth and a 4.1% organic growth despite the loss of exclusivity for Stelara [1][10] Group 1: Sales Performance - The Innovative Medicine segment achieved over $15 billion in sales for three consecutive quarters in 2025, marking the first time it surpassed $60 billion in full-year sales [2] - Key products such as Darzalex, Tremfya, and Erleada contributed significantly to growth, with Darzalex sales increasing by 23.0% to $14.35 billion, Erleada by 19.2% to $3.57 billion, and Tremfya by 40.5% to $5.2 billion [6][9] - The decline in Stelara sales by 41.3% to $6.08 billion in 2025 due to its loss of exclusivity negatively impacted the segment's growth by 1110 basis points [4][5] Group 2: Future Outlook - J&J anticipates accelerated growth in the Innovative Medicine segment in 2026, driven by key products and new launches, with expected growth of 5% to 7% from 2025 to 2030 [7][9] - The company expects a more pronounced impact from new products in 2026, including Rybrevant and Caplyta, following approvals in 2025 [7] - However, the impact of generic competition is expected to intensify in 2026, particularly for Stelara, Simponi, and Opsumit as they lose patent protection [8] Group 3: Competitive Landscape - J&J operates in key areas of immunology and oncology, facing competition from major drugmakers such as Novartis, AstraZeneca, AbbVie, and Amgen [10][11] Group 4: Stock Performance and Valuation - J&J's stock has outperformed the industry, rising 55.6% over the past year compared to an 18.0% increase in the industry [12] - The company's shares are currently trading at a price/earnings ratio of 20.63, higher than the industry average of 18.76 and above its five-year mean of 15.65 [14] - The Zacks Consensus Estimate for 2026 earnings has increased from $11.48 to $11.54, indicating positive sentiment [16]

Core Insights - U.S. sustainability policy is evolving, yet manufacturers are leveraging domestic production to achieve climate, governance, and workforce improvements [1] Group 1: Investment Trends - The reshoring movement has led to significant investments, with Apple committing over $500 billion to U.S. operations in the next four years and Johnson & Johnson planning to invest $55 billion in domestic production by 2029 [2] - Manufacturers are reassessing reshoring's potential for resilience and sustainability gains due to new tariffs affecting production costs [3] Group 2: Supply Chain and Operational Strategy - Supply chain disruptions from COVID-19 highlighted vulnerabilities, prompting companies like Caterpillar to prioritize reshoring while balancing sustainability and production costs [4] - Ahuja from Caterpillar noted that 70% of their dependency was on a single region, leading to efforts to mitigate single-country risks through optimization programs [5] Group 3: Decision-Making Factors - According to the 2025 Reshoring Survey Report, long-term sustainability and short- to medium-term profitability are primary factors influencing reshoring decisions, while environmental, social, and governance factors are less prioritized [6] - Companies are considering the reduction of supply chain and geographic risks as key opportunities for reshoring, alongside improved visibility into worker safety and regulatory compliance [6] Group 4: Success Metrics - Success metrics for reshoring may include reductions in scope 3 emissions, waste, water usage, and energy management, as well as improvements in job safety, job creation, sourcing, and traceability [7]

前半句是世界观，讲的是万物运行之道，后半句是方法论，告诉人们遇到问题应当怎么做。 第 58 章则把这一原理具体落脚到"祸福相依"这样一个日常的智慧当中，使之成为了人人都可以理解 和掌握的方便法门。 在投资和商业管理中，这一智慧同样适用。 " 反者道之动，弱者道之用。天下万物生于有，有生于无。 "—— 《道德经》第 40 章 " 祸兮，福之所倚；福兮，祸之所伏。孰知其极？其无正也。正复为奇，善复为妖。人之迷，其日固 久。 "—— 《道德经》第 58 章 反者道之动，弱者道之用 作者/ 舒泰峰 重阳投资合伙人、财经作家 著有《财富是认知的变现》、《财富善战者说》等 "反者道之动，弱者道之用"是《道德经》的最精彩表述之一，它的意思是说道的运行规律是循环往复 的，物极必反；而道发挥作用的方式则是柔弱谦下，顺势而为。 （一） 1982 年 9 月 29 日早晨，芝加哥一位 12 岁的小女孩玛丽 · 凯勒曼由于感冒吃了一粒泰诺，几分 钟后倒地身亡。同一天，又有几名互不相识的受害者相继暴毙。警方发现，这些受害者唯一的共同点 就是服用了泰诺胶囊。经检测，胶囊里被混入了氰化物，含量是致死量的 100 倍。 全美陷入疯抢退货潮， ...

Core Insights - The article discusses the characteristics of good dividend stocks, emphasizing the balance between dividend yield and growth track record [1][2] Dividend Performance - Over the last 50 years, S&P 500 companies that increased their dividends delivered a 10.2% average annual return, while those with no change returned 6.8% annually [2] - Companies with higher dividend payout ratios outperformed the market more often than those with lower ratios [2] Company Profiles Johnson & Johnson - Johnson & Johnson has a dividend yield of 2.2%, nearly double the S&P 500's yield of 1.2% [5] - The company has a record of increasing its dividend for 63 consecutive years, qualifying it as a Dividend King [5] - Johnson & Johnson generated $20 billion in free cash flow last year, covering its $12.4 billion in dividends [6] - The company invested $14.7 billion in R&D last year and completed a $14.6 billion acquisition of Intra-Cellular Therapies [8] Medtronic - Medtronic has a dividend yield of 2.8% and delivered its 48th consecutive annual dividend increase last year [9] - The company generated $5.2 billion in free cash flow during its 2025 fiscal year, covering the $3.6 billion in dividends paid out [11] - Medtronic invested $2.7 billion in R&D and agreed to acquire Cathworks for $585 million to enhance its growth profile [12] Investment Consideration - Both Johnson & Johnson and Medtronic are highlighted as strong dividend stocks due to their high-yielding and steadily growing dividends, making them suitable for income portfolios [13]

Group 1: Overview of Sierra Leone's Citizenship by Investment Program - The Sierra Leone Citizenship by Investment program offers a flexible and affordable pathway to citizenship, with a base price of $140,000 for the main applicant and discounts available for applicants of African descent [62][66] - The program allows for the inclusion of family members and business partners, making it one of the most affordable options globally for citizenship by investment [6][62] - The program is designed to attract high net worth individuals, providing them with opportunities to invest in a country with significant growth potential and low GDP per capita [46][47] Group 2: Economic and Investment Opportunities - Sierra Leone is focusing on sectors such as agriculture, infrastructure development, energy, and tourism to attract foreign direct investment [45][46] - The government is actively working to create a conducive environment for investors, including the establishment of the National Investment Board to facilitate investment processes [49][50] - The country offers unique opportunities for eco-tourism, with government support for developing eco-lodges and related infrastructure [52][55] Group 3: Banking and Financial Environment - Sierra Leone's banking sector is characterized by a focus on cash transactions, with no capital controls for local entities, making it easier for investors to manage their finances [26][33] - The banking system allows for efficient online banking services, enabling easy transfers and conversions without significant bureaucratic hurdles [31][33] - The country has not signed up for the Common Reporting Standard (CRS), providing a level of privacy for banking clients [26] Group 4: Political Stability and Governance - Sierra Leone is noted for its democratic stability, having undergone peaceful transitions of power, which enhances its attractiveness for foreign investment [22][39] - The government is committed to reforming immigration and investment laws to create a more favorable business environment [22][39] - The country has a strong emphasis on religious tolerance, which contributes to its social stability and peaceful coexistence among diverse communities [56][59] Group 5: Benefits of ECOWAS Membership - Citizenship in Sierra Leone provides access to the Economic Community of West African States (ECOWAS), allowing for easier travel and residence in 12 other West African countries [76][77] - This access simplifies the process for investors looking to expand their operations across the region, enhancing the overall value of Sierra Leonean citizenship [76][78] Group 6: Support for Investors - The Sierra Leone Citizenship by Investment program includes comprehensive support for new citizens, facilitating connections with government officials and providing assistance in navigating the investment landscape [70][72] - The program aims to remove bureaucratic obstacles, making it easier for investors to establish businesses and contribute to the local economy [74][75] - New citizens receive a free company setup and banking services, streamlining the investment process [70][72]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgent need for investment in AI technologies [1][13] - The energy demands of AI technologies are highlighted, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is positioned as a critical player in the AI energy sector, owning essential energy infrastructure assets that will benefit from the increasing energy demands of AI [3][7] - This company is described as a "toll booth" operator in the AI energy boom, profiting from the surge in electricity demand driven by AI advancements [4][5] Market Position - The company is noted for its unique capabilities in executing large-scale engineering, procurement, and construction (EPC) projects across various energy sectors, including nuclear energy, oil, gas, and renewables [7][8] - It is completely debt-free and has a significant cash reserve, amounting to nearly one-third of its market capitalization, which positions it favorably compared to other heavily indebted energy firms [8][10] Strategic Advantages - The company holds a substantial equity stake in another AI-related venture, providing investors with indirect exposure to multiple growth opportunities in the AI sector without the associated premium costs [9][10] - The company is benefiting from the onshoring trend driven by tariffs, which is expected to enhance its operational capabilities and market presence [6][14] Future Outlook - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, making investments in AI a strategic move for future growth [12] - The potential for significant returns is emphasized, with projections suggesting a possible 100% return within 12 to 24 months for investors who act now [15][19]

Core Insights - Johnson & Johnson announced 12-month pilot-phase data from the OMNY-AF study, indicating progress in their research efforts [1] - The company highlighted new findings related to the VARIPULSE Platform, suggesting advancements in technology and potential applications in the healthcare sector [1] Group 1 - The OMNY-AF study provides critical data that may influence future clinical practices and treatment options [1] - The VARIPULSE Platform's new findings could enhance the company's product offerings and competitive positioning in the market [1]